THE NETHERLANDS, March 5, 2015 - SynAffix BV, a biotechnology company exclusively focused on the development of industry-leading antibody-drug conjugate (ADC) technology platforms, today announced that it will present the new and underlying technologies used to generate enhanced ADCs at the 9th Annual BIO Europe Spring Conference on March 10 in Paris. Representing the latest technological advancement at SynAffix, HydraSpace™ uses novel proprietary linkers that enable even the most challenging hydrophobic payloads to be efficiently conjugated to antibodies. This results in the generation of stable ADC products at the desired drug-antibody ratio (homogeneous DAR2 or DAR4). Furthermore, this technology enables two different drug mechanisms to be incorporated into a single ADC therapeutic (DAR2+2 “dual warhead” ADCs). HydraSpace™ represents an addition to the proprietary underlying site-specific GlycoConnect™ technology of SynAffix, which does not require genetic modification of the antibody. This key advantage significantly reduces development timelines, enabling proof of concept ADCs to be generated from existing antibody material in a matter of weeks while retaining absolute versatility with respect to the combination of antibodies and payloads possible.
Prof. Floris van Delft, CSO of SynAffix added “We are proud to share results from various animal studies at Bio Europe, data that supports the superior therapeutic index of ADCs achieved using our proprietary technology compared to a marketed ADC. With the scalability required for clinical and commercial manufacturing already established and primate immunotoxicology studies planned for later this year, our technology is now just one step away from use in clinical trials.”
Date March 10, 2015
Time 2:30pm CET
Location Paris Expo - Porte de Versailles, Hall 5
About SynAffix BV
SynAffix BV, is a Netherlands-based biotechnology company backed by Aravis, BioGeneration Ventures, BOM Capital and MS Ventures, the strategic corporate venture capital fund of Merck Serono, the biopharmaceutical division of Merck.
SynAffix’s mission is to enable best-in-class targeted cancer therapeutics through its versatile glycoprotein modification technology, specifically designed to broaden the therapeutic index compared to currently available and emerging ADC therapeutics. Its proprietary approach results in therapeutics that are anticipated to not only come with an increased safety profile but are also more potent against a variety of different cancer types.
SynAffix’s vision is to be the preferred technology partner to enable the development of superior targeted cancer therapeutics through its proprietary GlycoConnect™ and HydraSpace™ technology platforms, allowing for first-in-human glycan-conjugated ADCs in 2016.
Issued for and on behalf of Synaffix by Instinctif Partners.
For more information please contact firstname.lastname@example.org